Navigation Links
Cequent to Present First Proof of Activity of an Oral RNAi Drug in Non-Human Primates at February Keystone Conference
Date:1/6/2009

CAMBRIDGE, Mass., Jan. 6 /PRNewswire/ -- Cequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based treatments to prevent and treat human disease, announced that the company has recently completed a successful toxicology study of its candidate CEQ501, an orally administered tkRNAi therapeutic targeting the primary oncogene (beta-catenin, CTNNB1) in FAP (familial adenomatous polyposis). FAP is an inherited gastrointestinal disease that causes hundreds of polyps to form in the colon. Today, without prophylactic removal of the colon, people with FAP almost inevitably develop colon cancer, and there is no medical treatment available. Cequent will present its findings, the first-ever proof of activity of an oral RNAi drug in non-human primates, in a poster at the Keystone Symposia Conference, Therapeutic Modulation of RNA Using Oligonucleotides. The conference will be held February 8 - 13 in Lake Louise, Alberta Canada.

"Delivery of RNAi into the targeted cells and tissues remains one of the biggest challenges in the development of RNAi-based therapeutics - a new class of drugs designed to work by effectively deactivating the specific gene or genes implicated in the progression of a disease," said Cequent President and CEO, Peter Parker. "We have shown previously in cell-culture assays and in a mouse model for human colon cancer that our tkRNAi technology effectively suppresses beta-catenin, a key oncogene in FAP. These new results are very encouraging, and represent another significant milestone in our work to turn the promise of RNAi into safe and effective therapies to treat devastating diseases, like FAP, and improve the lives of those affected."

The study showed that tkRNAi targeting beta-catenin was well tolerated at high dosing levels, with no product-related adverse events, no increase in serum cytokines, and no gross or histopathologic abnormalities noted. Orally administered bacteria expressing short hairpin RNA (shRNA) against beta-catenin significantly reduced messenger RNA (mRNA) levels of beta-catenin in the mucosa of the small and large intestine, an effect that was reversible after termination of dosing. Samples obtained from the gastrointestinal mucosa indicate that oral tkRNAi treatment was effective in up to 84 percent of animals, and target gene levels were suppressed between 58 to 64 percent compared to control animals. Pharmacokinetic studies verified the presence of the engineered shRNA in the intestinal mucosa, proving successful delivery of the active hairpin RNA component by the bacterial system. Cequent developed the current tkRNAi candidate on the basis of an E. coli delivery platform obtained from the laboratory of Patrice Courvalin at the Institut Pasteur. Cequent is planning to start a Phase I clinical trial for the indication of FAP in 2009.

About Cequent Pharmaceuticals, Inc. (www.cequentpharma.com)

An early-stage biopharmaceutical company, Cequent is pioneering the development of novel therapeutics to prevent and treat a wide range of human disorders - from inflammatory disease to cancer - based on the company's proprietary technology, TransKingdom RNA interference (tkRNAi). Cequent's first products, now in pre-clinical development, are drug candidates targeting colon-cancer prevention and inflammatory bowel disease. The company designed its powerful tkRNAi technology to deactivate specific disease-causing genes safely and effectively, using non-pathogenic bacteria as an engine to produce and deliver RNAi directly into cells. It is based on ground-breaking scientific research originating at the Institut Pasteur (Paris, France) and at the Beth Israel Deaconess Medical Center/Harvard Medical School. A privately held company based in Cambridge, Massachusetts, Cequent was established in 2006.


'/>"/>
SOURCE Cequent Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Cequent Pharmaceuticals Johannes Fruehauf, MD, Ph.D., to be Featured Speaker at RNAi World Congress in Boston - May 2, 2008
2. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
3. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
4. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
5. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
6. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
7. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
8. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
9. Iomai Announces Data from Phase 2 Field Study of Travelers Diarrhea Vaccine Accepted for Presentation at ICAAC
10. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
11. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... , April 26, 2017 Phoenix Marketing Solutions ... fifteenth year of fulfilling its mission of transforming science into ... highly scrutinized, Phoenix,s innovative approach supports ... community about the latest advances in science and medicine — ... was founded in 2002 by Tracy Doyle ...
(Date:4/24/2017)... England , April 24, 2017 ... development, today announced the addition of a major ... ,Validated In-situ Plate Seeding,). The VIPS has been ... and 384 well microplates as part of the ... system offers a simple and more reliable solution ...
(Date:4/20/2017)...  Vivify Health, the pioneer and market leader of ... very significant patent for the advancement of healthcare delivery ... digital health.  This landmark patent provides the company with ... Vivify,s position as the leader in remote care.  ... company to apply consumer mobile devices, wireless biometrics, EMR ...
Breaking Medicine Technology:
(Date:4/28/2017)... Washington, DC (PRWEB) , ... April 28, 2017 ... ... Unplanned Pregnancy (The National Campaign) announces its support for the Access to ... by Sen. Jeanne Shaheen (D-NH) and Rep. Jackie Speier (D-CA), will help to ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... integration of Microsoft(R) Word(TM) Online(TM), which enables sleep physicians to create and edit ... the reporting process and provides a familiar interface that does not require additional ...
(Date:4/28/2017)... ... April 28, 2017 , ... Getting enough sleep affects much more than energy – ... just 19 hours without sleep can compromise motor reaction time, which can increase the risk ... Insurance is sharing the following tips from the NSF to help you sleep better and ...
(Date:4/28/2017)... ... April 28, 2017 , ... Ushio America proudly introduces the ... instant energy-saving solution for F32T8 fluorescent lamps on most instant-start and programmed-start electronic ... hour rated lamps utilize the existing electronic ballast, saving labor and maintenance costs. ...
(Date:4/28/2017)... ... April 28, 2017 , ... Children ... to more adverse experiences than children in the general population. That’s because foster ... neglect or other family challenges. While no fault of their own, youth who ...
Breaking Medicine News(10 mins):